Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (67645)	9/14/1999 1:06:00 AM
From: JF Quinnelly	Read Replies (1) \| Respond to of 132070

Incyte acquired Synteni, a gene chip firm. That may be where the conflict arises. The Synteni chip doesn't appear to be a major portion of Incyte's business, so this may be a dramatic overreaction. Since I have both AFFX and INCY I just wish they would quit spending my funds on suing one another, dammit....

To: Knighty Tin who wrote (67645)	10/17/1999 5:07:00 AM
From: Doc Bones	Read Replies (2) \| Respond to of 132070

Mike, Taking you back, but can you elaborate on your remarks on INCY and AFFX and the 'ripoff'. I hold INCY and I've noticed that they seem to lose out in the publicity department to the flashier companies & CEOs. Here's a post of mine re the recent 'Nobel for Blobel' (BIO) and his 'connection' to HGSI (Reuters story excerpted), if you're interested: Message 11521203 Craig Venter finds his way into the news rather often too - usual story: Entrepreneur Craig is going to beat the Human Genome Project - no one else mentioned as in the race. If you can elaborate further on the 'ripoff' I'd like to hear. I assume it's nothing that will affect the stocks of INCY, AFFX ... (Any current wisdom on these and HGSI, Celera, etc. most welcome also) Thanks, Doc